<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-20403" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Allergy Immunotherapy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Persaud</surname>
            <given-names>Yudy</given-names>
          </name>
          <aff>Mt. Sinai</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Memon</surname>
            <given-names>Ruba J.</given-names>
          </name>
          <aff>Saint Joseph Mercy Oakland</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Savliwala</surname>
            <given-names>Mohammedi N.</given-names>
          </name>
          <aff>Saint Joseph Mercy Oakland</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yudy Persaud declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ruba Memon declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mohammedi Savliwala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>1</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-20403.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Allergy immunotherapy (AIT), which is also termed allergen desensitization or hypo-sensitization was first introduced by Leonard Noon and John Freeman in 1911. They proposed that people with hay fever were sensitive to grass pollen toxins. Desensitization is "a method, to develop a temporary state of tolerance to an agent responsible for an allergic or hypersensitivity reaction." This activity reviews the indications, contraindications, and techniques for allergy immunotherapy and highlights the role of the interprofessional team in the management of patients with allergies.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the indications for allergy immunotherapy.</p></list-item><list-item><p>Describe how allergy immunotherapy is done.</p></list-item><list-item><p>Outline the importance of collaboration and coordination within the interprofessional team in optimizing the care of patients requiring allergy immunotherapy.</p></list-item><list-item><p>Discuss future trends in allergy immunotherapy</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20403&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20403">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-20403.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Allergy immunotherapy (AIT), &#x000a0;also referred to as allergen desensitization or hypo-sensitization was first introduced by Leonard Noon and John Freeman in 1911, they proposed that people with hay fever were sensitive to grass pollen toxins. <xref ref-type="bibr" rid="article-20403.r1">[1]</xref>Noon is credited for developing a process involved in the extraction of timothy pollen in distilled water and then boiling it to create an extract.&#x000a0;<xref ref-type="bibr" rid="article-20403.r1">[1]</xref>&#x000a0;This extract was then injected in increasing doses to alleviate symptoms in patients.&#x000a0; This concept is widely in use today with a modified approach. Currently, the term immunotherapy is used to describe all methods to overcome abnormal immune responses with induction of clonal deletion, anergy, immune tolerance, and immune deviation. <xref ref-type="bibr" rid="article-20403.r2">[2]</xref>However, the term desensitization is "a method, to develop a temporary state of tolerance to an agent responsible for an allergic or hypersensitivity reaction." <xref ref-type="bibr" rid="article-20403.r3">[3]</xref>Furthermore, immunotherapy is a disease-modifying treatment and the effects can last longer even after stopping the treatment, which then provides prophylactic effects.<xref ref-type="bibr" rid="article-20403.r3">[3]</xref><xref ref-type="bibr" rid="article-20403.r4">[4]</xref><xref ref-type="bibr" rid="article-20403.r5">[5]</xref><xref ref-type="bibr" rid="article-20403.r6">[6]</xref><xref ref-type="bibr" rid="article-20403.r7">[7]</xref><xref ref-type="bibr" rid="article-20403.r8">[8]</xref></p>
      </sec>
      <sec id="article-20403.s3" sec-type="Anatomy and Physiology">
        <title>Anatomy and Physiology</title>
        <p>Several cellular and molecular mechanisms explain the beneficial effects of immunotherapy including allergic specific suppression of inducible CD4(+), CD 25+, forkhead box p3+ T-regulatory cells, and IL-10 secreting T-regulatory cells, preventing their increase in peripheral blood. Other mechanisms include suppression of eosinophils, mast cells, and basophils, and the switching of antibodies from IgE to IgG4 blocking antibodies.<xref ref-type="bibr" rid="article-20403.r9">[9]</xref><xref ref-type="bibr" rid="article-20403.r10">[10]</xref><xref ref-type="bibr" rid="article-20403.r11">[11]</xref>Other mechanisms, including a switch from a TH2 to a THI&#x000a0; immune deviation, &#x000a0;and other changes in humoral/cellular immunity, are still being elucidated.<xref ref-type="bibr" rid="article-20403.r10">[10]</xref><xref ref-type="bibr" rid="article-20403.r12">[12]</xref><xref ref-type="bibr" rid="article-20403.r13">[13]</xref><xref ref-type="bibr" rid="article-20403.r12">[12]</xref></p>
      </sec>
      <sec id="article-20403.s4" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>Indications for Allergen Immunotherapy</bold>
<xref ref-type="bibr" rid="article-20403.r2">[2]</xref>
<xref ref-type="bibr" rid="article-20403.r3">[3]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Moderate-to-severe allergic rhinitis</p>
          </list-item>
          <list-item>
            <p>Allergic asthma</p>
          </list-item>
          <list-item>
            <p>Allergic conjunctivitis</p>
          </list-item>
          <list-item>
            <p>Allergic rhino-conjunctivitis</p>
          </list-item>
          <list-item>
            <p>Atopic dermatitis</p>
          </list-item>
          <list-item>
            <p>Immune-mediated and IgE-mediated food allergy</p>
          </list-item>
          <list-item>
            <p>Insect allergy that causes significant local reaction and anaphylaxis</p>
          </list-item>
        </list>
        <p>Note: Allergen immunotherapy is only indicated when there is evidence of an IgE-mediated reaction that correlates with clinical symptoms. These IgE-mediated reactions can be identified via a blood IgE test or the more preferable skin testing.</p>
        <p>
<bold>Other Immunotherapies</bold>
<xref ref-type="bibr" rid="article-20403.r3">[3]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Vaccination and biological agents in infectious disease and primary immunodeficiencies.</p>
          </list-item>
          <list-item>
            <p>Immunosuppressive agents in autoimmune disease and organ transplant</p>
          </list-item>
          <list-item>
            <p>Biological and monoclonal agents</p>
          </list-item>
          <list-item>
            <p>Food hypersensitivity</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20403.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>There is no evidence to suggest that immunotherapy will be effective if a specific IgE antibody is negative.<xref ref-type="bibr" rid="article-20403.r3">[3]</xref>&#x000a0; Furthermore, if IgE testing results are positive but suspected clinical symptoms and exposure do not correlate, then it is also not likely to work.</p>
        <p>The use of concomitant B-blockers is contraindicated with immunotherapy in the rare chance that the patient needs epinephrine to treat anaphylaxis. However, according to the U.S. practice parameters on anaphylaxis, the benefits of Hymenoptera venom immunotherapy (VIT) outweigh the potential risks associated with b-blockers or ACEIs in patients with anaphylaxis to stinging insects who also have cardiovascular disease that requires these medications.&#x000a0;<xref ref-type="bibr" rid="article-20403.r14">[14]</xref> As per the EAACI guidelines, the risk/benefit profile also suggests that there should be no contraindication for venom immunotherapy in patients on B-blockers.&#x000a0;<xref ref-type="bibr" rid="article-20403.r15">[15]</xref></p>
        <p>If a patient is having an asthma exacerbation, they should not receive an immunotherapy injection&#x000a0;<xref ref-type="bibr" rid="article-20403.r2">[2]</xref></p>
      </sec>
      <sec id="article-20403.s6" sec-type="Equipment">
        <title>Equipment</title>
        <p>
<bold>Required Equipment and Procedures</bold>
<xref ref-type="bibr" rid="article-20403.r3">[3]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>All extracts require storage in a refrigerator at 4 C</p>
          </list-item>
          <list-item>
            <p>Administration can be done via subcutaneous injection or sublingually</p>
          </list-item>
          <list-item>
            <p>Seventy percent isopropanol for sanitization</p>
          </list-item>
          <list-item>
            <p>Sterile syringes and vials</p>
          </list-item>
          <list-item>
            <p>Mixing log with information on expiration</p>
          </list-item>
          <list-item>
            <p>Policy and procedure manual</p>
          </list-item>
          <list-item>
            <p>Emergency treatment, i.e epinephrine</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20403.s7" sec-type="Personnel">
        <title>Personnel</title>
        <p>Because allergy immunotherapy can cause severe reactions, including anaphylaxis, a physician should supervise trained personnel.<xref ref-type="bibr" rid="article-20403.r2">[2]</xref>&#x000a0;Required training include:<xref ref-type="bibr" rid="article-20403.r2">[2]</xref></p>
        <list list-type="bullet">
          <list-item>
            <p>Preparation of allergenic products</p>
          </list-item>
          <list-item>
            <p>Successful completion of a written test on aseptic technique and extract preparation and media-fill testing</p>
          </list-item>
          <list-item>
            <p>Knowledge of antiseptic hand cleaning and disinfection of mixing surfaces</p>
          </list-item>
          <list-item>
            <p>Ability to identify, measure, and mix different allergen extracts</p>
          </list-item>
          <list-item>
            <p>Understand who are the appropriate candidates for allergy immunotherapy</p>
          </list-item>
          <list-item>
            <p>Review with the patients the risk and benefits of the procedure</p>
          </list-item>
          <list-item>
            <p>Learn to identify signs and symptoms of a possible severe reaction</p>
          </list-item>
          <list-item>
            <p>Discuss with the patient what are some expectations during the course of treatment and when it will be successfully completed</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-20403.s8" sec-type="Preparation">
        <title>Preparation</title>
        <p>The prescribing physician should select allergen extracts based on IgE results and clinical correlation. The physician should consider several important factors including the quality of allergen extracts, cross-reactivity, and degradation of allergens and immunotherapy doses, for example, the starting dose should be lower than the maintenance dose.<xref ref-type="bibr" rid="article-20403.r2">[2]</xref> Keep in mind that some patients will not be able to achieve the maintenance dose due to possible side effects. There are also ranges of what are considered maintenance doses for standardized and non-standardized extracts.</p>
      </sec>
      <sec id="article-20403.s9" sec-type="Technique or Treatment">
        <title>Technique or Treatment</title>
        <p>Allergenic proteins from pollen, dander, dust mites, insects, mold, among others are the main ingredient of allergen extract.&#x000a0;However, the final product is a mixture of diluents or solvents and preservatives. Different extracts including aqueous, glycerinated, lyophilized, acetone precipitated, alum-precipitated are available. Diluents will keep the allergen in liquid form; commonly used agents are glycerin, phenol saline, and HSA. The staff should use measures that include good personal hygiene, hand washing, and antiseptics to clean working areas. These include a water-based disinfectant followed by the application of alcohol&#x000a0;on working surfaces for preparing allergen extracts. Alcohol kills organisms by dehydration. Sanitization will prevent bacterial contamination.<xref ref-type="bibr" rid="article-20403.r2">[2]</xref></p>
      </sec>
      <sec id="article-20403.s10" sec-type="Complications">
        <title>Complications</title>
        <p>Giving allergy immunotherapy should be given with tremendous care since it involves administering an agent that a patient is already known to be allergic to. Complications due to immunotherapy include systemic reactions such as anaphylaxis, large cutaneous reactions, and a local reaction at the injection site. <xref ref-type="bibr" rid="article-20403.r2">[2]</xref>&#x000a0;Although rare, even fatal reactions to subcutaneous allergy immunotherapy can occur.&#x000a0; One of the greatest risk factors for such reactions is asthma, especially uncontrolled or unstable asthma.<xref ref-type="bibr" rid="article-20403.r16">[16]</xref><xref ref-type="bibr" rid="article-20403.r17">[17]</xref>&#x000a0; &#x000a0;Another risk factor is an accidental intramuscular injection which can cause an increased risk of systemic reaction due to rapid absorption. Sublingual administration has only shown severe reactions associated with the first dose and subsequent doses cause less severe symptoms of the oral mucosa, throat, or gastrointestinal tract.&#x000a0;<xref ref-type="bibr" rid="article-20403.r18">[18]</xref><xref ref-type="bibr" rid="article-20403.r19">[19]</xref>&#x000a0; Due to these complications, patients must be aware of the risk vs benefits associated with immunotherapy. Thus, immunotherapy should be given under the guidance of a specialist trained in the field and informed consent should be gathered.</p>
        <p>
<bold>Management of Complications&#x000a0;</bold>
<xref ref-type="bibr" rid="article-20403.r2">[2]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Topical corticosteroids, antihistamines, or cool compresses for local reaction</p>
          </list-item>
          <list-item>
            <p>Epinephrine is the mainstay treatment for anaphylaxis.</p>
          </list-item>
        </list>
        <p>The physician should re-visit the benefit versus risk of continuing immunotherapy after systemic reactions.<xref ref-type="bibr" rid="article-20403.r2">[2]</xref></p>
      </sec>
      <sec id="article-20403.s11" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>
<bold>Asthma</bold>
</p>
        <p>Allergen immunotherapy can reduce short-term symptoms in allergic asthma; however, there is a moderate increase in the risk of systemic and local reactions based on a meta-analysis.<xref ref-type="bibr" rid="article-20403.r6">[6]</xref>&#x000a0;A 3-year course of either sublingual or subcutaneous immunotherapy prevents asthma for up to 2 years in children and adolescents with grass/birch pollen that triggers moderate to severe allergic rhinitis. However, this still requires further research.<xref ref-type="bibr" rid="article-20403.r4">[4]</xref></p>
        <p>Some studies have shown that giving immunotherapy for allergic rhinitis early can prevent the development of asthma in children.&#x000a0;<xref ref-type="bibr" rid="article-20403.r20">[20]</xref><xref ref-type="bibr" rid="article-20403.r21">[21]</xref><xref ref-type="bibr" rid="article-20403.r22">[22]</xref>&#x000a0;A study by Grembiale in 2000 showed that allergy immunotherapy to house dust mite helped to prevent the development of asthma.<xref ref-type="bibr" rid="article-20403.r22">[22]</xref>&#x000a0; In the preventative asthma study(PAT) children aged 5 to 12 years were given a subcutaneous injection of grass pollen and/or birch pollen for 3 years and was found to have a decrease in the development of asthma over a 10 year follow up. <xref ref-type="bibr" rid="article-20403.r20">[20]</xref>&#x000a0;In the Grass pollen asthma prevention trial (GAP), sublingual treatment with grass pollen also showed reduced asthma symptoms and medication scores.<xref ref-type="bibr" rid="article-20403.r21">[21]</xref></p>
        <p>
<bold>Allergic Rhinitis</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Allergen immunotherapy is clinically effective, cost-effective, and disease-modifying in allergic rhinitis compared to standard drugs.<xref ref-type="bibr" rid="article-20403.r23">[23]</xref><xref ref-type="bibr" rid="article-20403.r24">[24]</xref></p>
          </list-item>
          <list-item>
            <p>Sublingual immunotherapy for pediatric allergic rhinitis has shown&#x000a0;improvement in symptomatic management&#x000a0;and a decreased medication need based on a meta-analysis of the randomized controlled trials. More trials with a larger sample size are underway to assess safety in the pediatric population.<xref ref-type="bibr" rid="article-20403.r25">[25]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Allergic Rhino-Conjunctivitis</bold>
</p>
        <p>Allergen immunotherapy is beneficial in ameliorating rhino-conjunctivitis symptoms.&#x000a0;<xref ref-type="bibr" rid="article-20403.r26">[26]</xref>Some evidence suggests that there is a&#x000a0;maintenance&#x000a0;effect on reducing symptoms after discontinuation of immunotherapy.<xref ref-type="bibr" rid="article-20403.r27">[27]</xref></p>
      </sec>
      <sec id="article-20403.s12" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>
<bold>Current and Future Trends in Allergen Immunotherapy</bold>
</p>
        <p>&#x000a0;Recent advances in understanding the mechanism and the long-term effects of immunotherapy are encouraging for future therapies. There are also new approaches being used to improve safety and&#x000a0;overcoming the risk of severe adverse allergic reactions during immunotherapy. Newer allergen preparations available include allergoids, recombinant allergens (recA), and modified-recombinant allergens (recA). Studies on virus-like particles and CpG-motifs, adjuvants like MPL, and aluminum hydroxide have been shown to increase immunological response and can improve safety and efficacy.<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www-ncbi-nlm-nih-gov.eresources.mssm.edu/books/NBK535367/?report=classic">[8]</ext-link>&#x000a0; Other newer approaches to allergen immunotherapy include the&#x000a0;application of extract patches on the skin and/or inguinal lymph node injection.&#x000a0;Furthermore, recombinant technology or chemicals may alter allergen molecules that make them less reactive; this may be due to suppression of Th2 responses or stimulation of toll-like receptors (approval is pending).<xref ref-type="bibr" rid="article-20403.r28">[28]</xref>&#x000a0;The new advances in allergy immunotherapy not only provide disease-modifying treatments but are also cost-effective&#x000a0;and improve the quality of life.<xref ref-type="bibr" rid="article-20403.r29">[29]</xref>&#x000a0;Yet, with the historical efficacy and safety of immunotherapy, it remains underutilized.</p>
        <p>
<bold>Safety, Doses, Delivery, and Application of Immunotherapy&#x000a0;</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Comparison of pediatric and adult systemic reactions to subcutaneous immunotherapy shows significant Grade 1 and Grade 2 systemic reactions that are higher in a pediatric population than adults. However, further studies are needed to evaluate the dosing strategy in children.<xref ref-type="bibr" rid="article-20403.r30">[30]</xref></p>
          </list-item>
          <list-item>
            <p>Subcutaneous allergen immunotherapy has shown that SCIT rarely causes any major clinical problems; there is a&#x000a0;risk of less than 1.5% in patients who are HIV positive without AIDS, cancer (in remission), severe asthma, transplantation,&#x000a0; and during pregnancy, based on web-based survey.<xref ref-type="bibr" rid="article-20403.r31">[31]</xref></p>
          </list-item>
          <list-item>
            <p>Food immunotherapy has exploded due to numerous studies suggestive of its benefit.&#x000a0; One such study was the LEAP (Learning Early About Peanut Allergy) that showed that high-risk infants with atopic dermatitis and egg allergy were able to build a tolerance to the ingestion of peanut if given early.<xref ref-type="bibr" rid="article-20403.r32">[32]</xref>&#x000a0;Studies investigating oral immunotherapy with other foods and various delivery methods are currently being done.</p>
          </list-item>
        </list>
        <p>Future trends in allergy immunotherapy support the concept of precision medicine. It should always be individualized and specific for a particular patient. Although it has been shown to prevent the development of asthma and new sensitization, this has only been shown in children. On the other hand, adults should be evaluated differently, and it should be used for the primary objective of bringing relief to their allergic symptoms. Further research is needed to address research gaps in allergy immunotherapy.&#x000a0; Such gaps include which sensitivities should be targeted to prevent disease, timing of immunotherapy, length of treatment, monoallergen vs polyallergen treatment, etc. However, the future is exciting, and with the increasing understanding of the immune system, the age of precision medicine has arrived.</p>
      </sec>
      <sec id="article-20403.s13" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>When using allergy immunotherapy, an interprofessional team including clinicians, mid-level practitioners nursing staff, and pharmacists is the best approach to achieving improved patient outcomes.</p>
      </sec>
      <sec id="article-20403.s14" sec-type="Nursing, Allied Health, and Interprofessional Team Monitoring">
        <title>Nursing, Allied Health, and Interprofessional Team Monitoring</title>
        <p>When administering allergy&#x000a0;immunotherapy, an interprofessional team including clinicians, mid-level practitioners, and nursing staff should be vigilant in looking for signs of an allergic reaction.&#x000a0;</p>
      </sec>
      <sec id="article-20403.s15">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=20403&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=20403">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/20403/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=20403">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-20403.s16">
        <title>References</title>
        <ref id="article-20403.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>NOON</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Prophylactic inoculation against hay fever (historical document).</article-title>
            <source>Ann Allergy</source>
            <year>1955</year>
            <season>Nov-Dec</season>
            <volume>13</volume>
            <issue>6</issue>
            <fpage>713</fpage>
            <page-range>713-6; passim</page-range>
            <pub-id pub-id-type="pmid">13268980</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cox</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Lockey</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Calabria</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chacko</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Finegold</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Weber</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Blessing-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Portnoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Tilles</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Allergen immunotherapy: a practice parameter third update.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2011</year>
            <month>Jan</month>
            <volume>127</volume>
            <issue>1 Suppl</issue>
            <fpage>S1</fpage>
            <page-range>S1-55</page-range>
            <pub-id pub-id-type="pmid">21122901</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanno</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Calderon</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Sanchez-Borges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rosenwasser</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Bousquet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pawankar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sisul</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Cepeda</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fineman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sublett</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Katelaris</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>YS</given-names>
              </name>
              <name>
                <surname>Moon</surname>
                <given-names>HB</given-names>
              </name>
              <name>
                <surname>Casale</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Demoly</surname>
                <given-names>P</given-names>
              </name>
              <collab>Joint Allergy Academies</collab>
            </person-group>
            <article-title>Revisiting Desensitization and Allergen Immunotherapy Concepts for the International Classification of Diseases (ICD)-11.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2016</year>
            <season>Jul-Aug</season>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>643</fpage>
            <page-range>643-9</page-range>
            <pub-id pub-id-type="pmid">26969269</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Halken</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Calder&#x000f3;n</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Angier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Agache</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Ansotegui</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Arasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Du Toit</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fernandez-Rivas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Geerth van Wijk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jutel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kleine-Tebbe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matricardi</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Pajno</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Penagos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Sturm</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Timmermans</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van Ree</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Wahn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kristiansen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dhami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>EAACI guidelines on allergen immunotherapy: Prevention of allergy.</article-title>
            <source>Pediatr Allergy Immunol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>728</fpage>
            <page-range>728-745</page-range>
            <pub-id pub-id-type="pmid">28902467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Di Lorenzo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leto-Barone</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>La Piana</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Plaia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Di Bona</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>The effect of allergen immunotherapy in the onset of new sensitizations: a meta-analysis.</article-title>
            <source>Int Forum Allergy Rhinol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>7</volume>
            <issue>7</issue>
            <fpage>660</fpage>
            <page-range>660-669</page-range>
            <pub-id pub-id-type="pmid">28544523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kakourou</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asamoah</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Agache</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jutel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Bonini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cavkaytar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Flood</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gajdanowicz</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Izuhara</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Kalayci</surname>
                <given-names>&#x000d6;</given-names>
              </name>
              <name>
                <surname>Mosges</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Palomares</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Smolinska</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sokolowska</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Asaria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Netuveli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Zaman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Akhlaq</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis.</article-title>
            <source>Allergy</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>72</volume>
            <issue>12</issue>
            <fpage>1825</fpage>
            <page-range>1825-1848</page-range>
            <pub-id pub-id-type="pmid">28543086</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kristiansen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dhami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Netuveli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Halken</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Calder&#x000f3;n</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Penagos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Du Toit</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ansotegui</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Kleine-Tebbe</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matricardi</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Pajno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Timmermanns</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Wahn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Allergen immunotherapy for the prevention of allergy: A systematic review and meta-analysis.</article-title>
            <source>Pediatr Allergy Immunol</source>
            <year>2017</year>
            <month>Feb</month>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-29</page-range>
            <pub-id pub-id-type="pmid">27653623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klimek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Bousquet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Senti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>K&#x000fc;ndig</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Allergen immunotherapy in allergic rhinitis: current use and future trends.</article-title>
            <source>Expert Rev Clin Immunol</source>
            <year>2017</year>
            <month>Sep</month>
            <volume>13</volume>
            <issue>9</issue>
            <fpage>897</fpage>
            <page-range>897-906</page-range>
            <pub-id pub-id-type="pmid">28532268</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jutel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Immunological mechanisms of allergen-specific immunotherapy.</article-title>
            <source>Allergy</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>66</volume>
            <issue>6</issue>
            <fpage>725</fpage>
            <page-range>725-32</page-range>
            <pub-id pub-id-type="pmid">21466562</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>James</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Durham</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Update on mechanisms of allergen injection immunotherapy.</article-title>
            <source>Clin Exp Allergy</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>1074</fpage>
            <page-range>1074-88</page-range>
            <pub-id pub-id-type="pmid">18691292</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van de Veen</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Stanic</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Yaman</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Wawrzyniak</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>S&#x000f6;llner</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>R&#x000fc;ckert</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>131</volume>
            <issue>4</issue>
            <fpage>1204</fpage>
            <page-range>1204-12</page-range>
            <pub-id pub-id-type="pmid">23453135</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shamji</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Durham</surname>
                <given-names>SR</given-names>
              </name>
            </person-group>
            <article-title>Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>140</volume>
            <issue>6</issue>
            <fpage>1485</fpage>
            <page-range>1485-1498</page-range>
            <pub-id pub-id-type="pmid">29221580</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gold</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Antignano</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Halim</surname>
                <given-names>TY</given-names>
              </name>
              <name>
                <surname>Hirota</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Blanchet</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Zaph</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Takei</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>McNagny</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Group 2 innate lymphoid cells facilitate sensitization to local, but not systemic, TH2-inducing allergen exposures.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>133</volume>
            <issue>4</issue>
            <fpage>1142</fpage>
            <page-range>1142-8</page-range>
            <pub-id pub-id-type="pmid">24679471</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lieberman</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Nicklas</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Randolph</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oppenheimer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bernstein</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ellis</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Golden</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Greenberger</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Kemp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ledford</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lieberman</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Metcalfe</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Nowak-Wegrzyn</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sicherer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Wallace</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Blessing-Moore</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Portnoy</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Schuller</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spector</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tilles</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis--a practice parameter update 2015.</article-title>
            <source>Ann Allergy Asthma Immunol</source>
            <year>2015</year>
            <month>Nov</month>
            <volume>115</volume>
            <issue>5</issue>
            <fpage>341</fpage>
            <page-range>341-84</page-range>
            <pub-id pub-id-type="pmid">26505932</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sturm</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Mosbech</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Bil&#x000f2;</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Akdis</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Antol&#x000ed;n-Am&#x000e9;rigo</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Cichocka-Jarosz</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gawlik</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jakob</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kosnik</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mingomataj</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mitsias</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Ollert</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Oude Elberink</surname>
                <given-names>JNG</given-names>
              </name>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Pitsios</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pravettoni</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ru&#x000eb;ff</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sin</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Agache</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Angier</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Arasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Calder&#x000f3;n</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fernandez-Rivas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Halken</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jutel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lau</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pajno</surname>
                <given-names>GB</given-names>
              </name>
              <name>
                <surname>van Ree</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Spranger</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>van Wijk</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Dhami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zaman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy.</article-title>
            <source>Allergy</source>
            <year>2018</year>
            <month>Apr</month>
            <volume>73</volume>
            <issue>4</issue>
            <fpage>744</fpage>
            <page-range>744-764</page-range>
            <pub-id pub-id-type="pmid">28748641</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reid</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lockey</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Turkeltaub</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Platts-Mills</surname>
                <given-names>TA</given-names>
              </name>
            </person-group>
            <article-title>Survey of fatalities from skin testing and immunotherapy 1985-1989.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>1993</year>
            <month>Jul</month>
            <volume>92</volume>
            <issue>1 Pt 1</issue>
            <fpage>6</fpage>
            <page-range>6-15</page-range>
            <pub-id pub-id-type="pmid">8335856</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Wanner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Borish</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Liss</surname>
                <given-names>GM</given-names>
              </name>
              <collab>Immunotherapy Committee, American Academy of Allergy, Asthma and Immunology</collab>
            </person-group>
            <article-title>Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2004</year>
            <month>Jun</month>
            <volume>113</volume>
            <issue>6</issue>
            <fpage>1129</fpage>
            <page-range>1129-36</page-range>
            <pub-id pub-id-type="pmid">15208595</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernstein</surname>
                <given-names>DI</given-names>
              </name>
              <name>
                <surname>Bardelas</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Svanholm Fogh</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Nolte</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A practical guide to the sublingual immunotherapy tablet adverse event profile: implications for clinical practice.</article-title>
            <source>Postgrad Med</source>
            <year>2017</year>
            <month>Aug</month>
            <volume>129</volume>
            <issue>6</issue>
            <fpage>590</fpage>
            <page-range>590-597</page-range>
            <pub-id pub-id-type="pmid">28326906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nolte</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Casale</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Lockey</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Fogh</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Kaur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2017</year>
            <season>Jan-Feb</season>
            <volume>5</volume>
            <issue>1</issue>
            <fpage>84</fpage>
            <page-range>84-89.e3</page-range>
            <pub-id pub-id-type="pmid">27838323</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jacobsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Niggemann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Dreborg</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ferdousi</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Halken</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>H&#x000f8;st</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koivikko</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Norberg</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Valovirta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wahn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>M&#x000f6;ller</surname>
                <given-names>C</given-names>
              </name>
              <collab>(The PAT investigator group)</collab>
            </person-group>
            <article-title>Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study.</article-title>
            <source>Allergy</source>
            <year>2007</year>
            <month>Aug</month>
            <volume>62</volume>
            <issue>8</issue>
            <fpage>943</fpage>
            <page-range>943-8</page-range>
            <pub-id pub-id-type="pmid">17620073</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valovirta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Petersen</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Piotrowska</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Laursen</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Andersen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>S&#x000f8;rensen</surname>
                <given-names>HF</given-names>
              </name>
              <name>
                <surname>Klink</surname>
                <given-names>R</given-names>
              </name>
              <collab>GAP investigators</collab>
            </person-group>
            <article-title>Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy.</article-title>
            <source>J Allergy Clin Immunol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>141</volume>
            <issue>2</issue>
            <fpage>529</fpage>
            <page-range>529-538.e13</page-range>
            <pub-id pub-id-type="pmid">28689794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grembiale</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Camporota</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Naty</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tranfa</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Djukanovic</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Marsico</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Effects of specific immunotherapy in allergic rhinitic individuals with bronchial hyperresponsiveness.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2000</year>
            <month>Dec</month>
            <volume>162</volume>
            <issue>6</issue>
            <fpage>2048</fpage>
            <page-range>2048-52</page-range>
            <pub-id pub-id-type="pmid">11112112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cox</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>The role of allergen immunotherapy in the management of allergic rhinitis.</article-title>
            <source>Am J Rhinol Allergy</source>
            <year>2016</year>
            <season>Jan-Feb</season>
            <volume>30</volume>
            <issue>1</issue>
            <fpage>48</fpage>
            <page-range>48-53</page-range>
            <pub-id pub-id-type="pmid">26867530</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Makatsori</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Calderon</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>Subcutaneous Immunotherapy and Sublingual Immunotherapy: Comparative Efficacy, Current and Potential Indications, and Warnings--United States Versus Europe.</article-title>
            <source>Immunol Allergy Clin North Am</source>
            <year>2016</year>
            <month>Feb</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-24</page-range>
            <pub-id pub-id-type="pmid">26617224</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feng</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and safety of sublingual immunotherapy for allergic rhinitis in pediatric patients: A meta-analysis of randomized controlled trials.</article-title>
            <source>Am J Rhinol Allergy</source>
            <year>2017</year>
            <month>Jan</month>
            <day>01</day>
            <volume>31</volume>
            <issue>1</issue>
            <fpage>27</fpage>
            <page-range>27-35</page-range>
            <pub-id pub-id-type="pmid">28234149</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Demoly</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gerth van Wijk</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Bonini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bousquet</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Canonica</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Durham</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Malling</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>M&#x000f6;sges</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Papadopoulos</surname>
                <given-names>NG</given-names>
              </name>
              <name>
                <surname>Rak</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Rodriguez del Rio</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Valovirta</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Wahn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Calderon</surname>
                <given-names>MA</given-names>
              </name>
              <collab>European Academy of Allergy and Clinical Immunology</collab>
            </person-group>
            <article-title>Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper.</article-title>
            <source>Allergy</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>69</volume>
            <issue>7</issue>
            <fpage>854</fpage>
            <page-range>854-67</page-range>
            <pub-id pub-id-type="pmid">24761804</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Nurmatov</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Arasi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Asaria</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zaman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Netuveli</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Pfaar</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Muraro</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ansotegui</surname>
                <given-names>IJ</given-names>
              </name>
              <name>
                <surname>Calderon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Cingi</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Durham</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>van Wijk</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Halken</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hamelmann</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hellings</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jacobsen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Knol</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maggina</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>M&#x000f6;sges</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Oude Elberink</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Pajno</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Panwankar</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pastorello</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Penagos</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pitsios</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Rotiroti</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Timmermans</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Tsilochristou</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Varga</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Schmidt-Weber</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wilkinson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Worm</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Allergen immunotherapy for allergic rhinoconjunctivitis: A systematic review and meta-analysis.</article-title>
            <source>Allergy</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>72</volume>
            <issue>11</issue>
            <fpage>1597</fpage>
            <page-range>1597-1631</page-range>
            <pub-id pub-id-type="pmid">28493631</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>HS</given-names>
              </name>
            </person-group>
            <article-title>Allergen immunotherapy now and in the future.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>4</issue>
            <fpage>268</fpage>
            <page-range>268-72</page-range>
            <pub-id pub-id-type="pmid">27401313</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reisacher</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Schwanke</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>New advances in allergy immunotherapy.</article-title>
            <source>Curr Opin Otolaryngol Head Neck Surg</source>
            <year>2016</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>231</fpage>
            <page-range>231-7</page-range>
            <pub-id pub-id-type="pmid">26926847</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lim</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Sison</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Ponda</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Comparison of Pediatric and Adult Systemic Reactions to Subcutaneous Immunotherapy.</article-title>
            <source>J Allergy Clin Immunol Pract</source>
            <year>2017</year>
            <season>Sep-Oct</season>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>1241</fpage>
            <page-range>1241-1247.e2</page-range>
            <pub-id pub-id-type="pmid">28341172</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Larenas-Linnemann</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hauswirth</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Calabria</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Sher</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Rank</surname>
                <given-names>MA</given-names>
              </name>
            </person-group>
            <article-title>American Academy of Allergy, Asthma &#x00026; Immunology membership experience with allergen immunotherapy safety in patients with specific medical conditions.</article-title>
            <source>Allergy Asthma Proc</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>37</volume>
            <issue>5</issue>
            <fpage>112</fpage>
            <page-range>112-22</page-range>
            <pub-id pub-id-type="pmid">27657518</pub-id>
          </element-citation>
        </ref>
        <ref id="article-20403.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Du Toit</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sayre</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Sever</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Lawson</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bahnson</surname>
                <given-names>HT</given-names>
              </name>
              <name>
                <surname>Brough</surname>
                <given-names>HA</given-names>
              </name>
              <name>
                <surname>Santos</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Radulovic</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Basting</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Turcanu</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Plaut</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lack</surname>
                <given-names>G</given-names>
              </name>
              <collab>Immune Tolerance Network LEAP-On Study Team</collab>
            </person-group>
            <article-title>Effect of Avoidance on Peanut Allergy after Early Peanut Consumption.</article-title>
            <source>N Engl J Med</source>
            <year>2016</year>
            <month>Apr</month>
            <day>14</day>
            <volume>374</volume>
            <issue>15</issue>
            <fpage>1435</fpage>
            <page-range>1435-43</page-range>
            <pub-id pub-id-type="pmid">26942922</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
